Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

In vitro susceptibility of urinary Escherichia coli isolates to first- and second-line empirically prescribed oral antimicrobials: CANWARD surveillance study results for Canadian outpatients, 2007-2016.

Karlowsky JA, Lagacé-Wiens PRS, Adam HJ, Baxter MR, Laing NM, Walkty AJ, Zhanel GG.

Int J Antimicrob Agents. 2019 Jul;54(1):62-68. doi: 10.1016/j.ijantimicag.2019.04.012. Epub 2019 Apr 26.

PMID:
31034938
2.

Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.

Zhanel GG, Golden AR, Zelenitsky S, Wiebe K, Lawrence CK, Adam HJ, Idowu T, Domalaon R, Schweizer F, Zhanel MA, Lagacé-Wiens PRS, Walkty AJ, Noreddin A, Lynch Iii JP, Karlowsky JA.

Drugs. 2019 Feb;79(3):271-289. doi: 10.1007/s40265-019-1055-2. Review.

PMID:
30712199
3.

Frequency of 16S ribosomal RNA methyltransferase detection among Escherichia coli and Klebsiella pneumoniae clinical isolates obtained from patients in Canadian hospitals (CANWARD, 2013-2017).

Walkty A, Karlowsky JA, Baxter MR, Adam HJ, Boyd D, Bharat A, Mulvey MR, Charles M, Bergevin M, Zhanel GG.

Diagn Microbiol Infect Dis. 2019 Jun;94(2):199-201. doi: 10.1016/j.diagmicrobio.2018.12.005. Epub 2018 Dec 14.

PMID:
30638654
4.

Antimicrobial-resistant pathogens in Canadian ICUs: results of the CANWARD 2007 to 2016 study.

Denisuik AJ, Garbutt LA, Golden AR, Adam HJ, Baxter M, Nichol KA, Lagacé-Wiens P, Walkty AJ, Karlowsky JA, Hoban DJ, Mulvey MR, Zhanel GG.

J Antimicrob Chemother. 2019 Mar 1;74(3):645-653. doi: 10.1093/jac/dky477.

PMID:
30500898
5.

In Vitro Activity of Sulopenem, an Oral Penem, against Urinary Isolates of Escherichia coli.

Karlowsky JA, Adam HJ, Baxter MR, Denisuik AJ, Lagacé-Wiens PRS, Walkty AJ, Puttagunta S, Dunne MW, Zhanel GG.

Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e01832-18. doi: 10.1128/AAC.01832-18. Print 2019 Jan.

6.

In Vitro Activity of Plazomicin against Gram-Negative and Gram-Positive Bacterial Pathogens Isolated from Patients in Canadian Hospitals from 2013 to 2017 as Part of the CANWARD Surveillance Study.

Walkty A, Karlowsky JA, Baxter MR, Adam HJ, Zhanel GG.

Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e02068-18. doi: 10.1128/AAC.02068-18. Print 2019 Jan.

7.

Molecular characterization of predominant Streptococcus pneumoniae serotypes causing invasive infections in Canada: the SAVE study, 2011-15.

Golden AR, Adam HJ, Karlowsky JA, Baxter M, Nichol KA, Martin I, Demczuk W, Van Caeseele P, Gubbay JB, Lefebvre B, Levett PN, Zahariadis G, Haldane D, Gad R, German G, Gilmour MW, Mulvey MR, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA).

J Antimicrob Chemother. 2018 Jul 1;73(suppl_7):vii20-vii31. doi: 10.1093/jac/dky157.

PMID:
29982573
8.

Analysis of multidrug resistance in the predominant Streptococcus pneumoniae serotypes in Canada: the SAVE study, 2011-15.

Adam HJ, Golden AR, Karlowsky JA, Baxter MR, Nichol KA, Martin I, Demczuk W, Mulvey MR, Gilmour MW, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA).

J Antimicrob Chemother. 2018 Jul 1;73(suppl_7):vii12-vii19. doi: 10.1093/jac/dky158.

PMID:
29982572
9.
10.

Antimicrobial susceptibility testing of invasive isolates of Streptococcus pneumoniae from Canadian patients: the SAVE study, 2011-15.

Karlowsky JA, Adam HJ, Golden AR, Baxter MR, Nichol KA, Martin I, Demczuk W, Mulvey MR, Gilmour MW, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA).

J Antimicrob Chemother. 2018 Jul 1;73(suppl_7):vii5-vii11. doi: 10.1093/jac/dky156.

PMID:
29982570
11.

Evaluation of three MALDI-TOF mass spectrometry libraries for the identification of filamentous fungi in three clinical microbiology laboratories in Manitoba, Canada.

Stein M, Tran V, Nichol KA, Lagacé-Wiens P, Pieroni P, Adam HJ, Turenne C, Walkty AJ, Normand AC, Hendrickx M, Piarroux R, Karlowsky JA.

Mycoses. 2018 Oct;61(10):743-753. doi: 10.1111/myc.12800. Epub 2018 Jul 2.

PMID:
29893421
12.

Canadian recommendations for laboratory interpretation of multiple or extensive drug resistance in clinical isolates of Enterobacteriaceae, Acinetobacter species and Pseudomonas aeruginosa.

German GJ, Gilmour M, Tipples G, Adam HJ, Almohri H, Bullard J, Dingle T, Farrell D, Girouard G, Haldane D, Hoang L, Levett PN, Melano R, Minion J, Needle R, Patel SN, Rennie R, Reyes RC, Longtin J, Mulvey MR.

Can Commun Dis Rep. 2018 Jan 4;44(1):29-34. eCollection 2018 Jan 4.

13.

PCR ribotyping and antimicrobial susceptibility testing of isolates of Clostridium difficile cultured from toxin-positive diarrheal stools of patients receiving medical care in Canadian hospitals: the Canadian Clostridium difficile Surveillance Study (CAN-DIFF) 2013-2015.

Karlowsky JA, Adam HJ, Kosowan T, Baxter MR, Nichol KA, Laing NM, Golding G, Zhanel GG.

Diagn Microbiol Infect Dis. 2018 Jun;91(2):105-111. doi: 10.1016/j.diagmicrobio.2018.01.017. Epub 2018 Jan 31.

PMID:
29456070
14.

In vitro activity of eravacycline against 2213 Gram-negative and 2424 Gram-positive bacterial pathogens isolated in Canadian hospital laboratories: CANWARD surveillance study 2014-2015.

Zhanel GG, Baxter MR, Adam HJ, Sutcliffe J, Karlowsky JA.

Diagn Microbiol Infect Dis. 2018 May;91(1):55-62. doi: 10.1016/j.diagmicrobio.2017.12.013. Epub 2017 Dec 22.

PMID:
29338931
15.

Antimicrobial susceptibility of clinical isolates of Neisseria gonorrhoeae to alternative antimicrobials with therapeutic potential.

Lagacé-Wiens PRS, Adam HJ, Laing NM, Baxter MR, Martin I, Mulvey MR, Karlowsky JA, Hoban DJ, Zhanel GG.

J Antimicrob Chemother. 2017 Aug 1;72(8):2273-2277. doi: 10.1093/jac/dkx147.

PMID:
28505331
16.

In vitro activity of Oritavancin against gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2015.

Karlowsky JA, Walkty AJ, Baxter MR, Arhin FF, Moeck G, Adam HJ, Zhanel GG.

Diagn Microbiol Infect Dis. 2017 Apr;87(4):349-356. doi: 10.1016/j.diagmicrobio.2017.01.006. Epub 2017 Jan 20.

PMID:
28159446
17.

Frequency of MCR-1-mediated colistin resistance among Escherichia coli clinical isolates obtained from patients in Canadian hospitals (CANWARD 2008-2015).

Walkty A, Karlowsky JA, Adam HJ, Lagacé-Wiens P, Baxter M, Mulvey MR, McCracken M, Poutanen SM, Roscoe D, Zhanel GG.

CMAJ Open. 2016 Oct 26;4(4):E641-E645. doi: 10.9778/cmajo.20160080. eCollection 2016 Oct-Dec.

18.

Invasive Streptococcus pneumoniae in Canada, 2011-2014: Characterization of new candidate 15-valent pneumococcal conjugate vaccine serotypes 22F and 33F.

Golden AR, Adam HJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA).

Vaccine. 2016 May 17;34(23):2527-30. doi: 10.1016/j.vaccine.2016.03.058. Epub 2016 Apr 13.

PMID:
27085174
19.

Characterization of MDR and XDR Streptococcus pneumoniae in Canada, 2007-13.

Golden AR, Rosenthal M, Fultz B, Nichol KA, Adam HJ, Gilmour MW, Baxter MR, Hoban DJ, Karlowsky JA, Zhanel GG.

J Antimicrob Chemother. 2015 Aug;70(8):2199-202. doi: 10.1093/jac/dkv107. Epub 2015 Apr 28.

PMID:
25921512
20.

In vitro activity of ceftazidime-avibactam against 338 molecularly characterized gentamicin-nonsusceptible Gram-negative clinical isolates obtained from patients in Canadian hospitals.

Denisuik AJ, Karlowsky JA, Denisuik T, Nichols WW, Keating TA, Adam HJ, Baxter M, Walkty A, Zhanel GG.

Antimicrob Agents Chemother. 2015;59(6):3623-6. doi: 10.1128/AAC.00364-15. Epub 2015 Mar 30.

21.

Assessment of multidrug resistance, clonality and virulence in non-PCV-13 Streptococcus pneumoniae serotypes in Canada, 2011-13.

Golden AR, Adam HJ, Gilmour MW, Baxter MR, Martin I, Nichol KA, Demczuk WH, Hoban DJ, Zhanel GG.

J Antimicrob Chemother. 2015 Jul;70(7):1960-4. doi: 10.1093/jac/dkv061. Epub 2015 Mar 11.

PMID:
25761605
22.

In vitro activity of oritavancin against Gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2013.

Karlowsky JA, Walkty AJ, Baxter MR, Adam HJ, Zhanel GG.

Diagn Microbiol Infect Dis. 2014 Dec;80(4):311-5. doi: 10.1016/j.diagmicrobio.2014.09.003. Epub 2014 Sep 16.

PMID:
25294303
23.

Pharmacodynamic activity of ertapenem versus genotypically characterized extended-spectrum β-lactamase (ESBL)-, KPC- or NDM-producing Escherichia coli with reduced susceptibility or resistance to ertapenem using an in vitro model.

Zhanel GG, Denisuik A, Vashisht S, Yachison C, Adam HJ, Hoban DJ.

J Antimicrob Chemother. 2014 Sep;69(9):2448-52. doi: 10.1093/jac/dku149. Epub 2014 May 14.

PMID:
24827891
24.

In Vitro activity of fosfomycin against Escherichia coli isolated from patients with urinary tract infections in Canada as part of the CANWARD surveillance study.

Karlowsky JA, Denisuik AJ, Lagacé-Wiens PR, Adam HJ, Baxter MR, Hoban DJ, Zhanel GG.

Antimicrob Agents Chemother. 2014;58(2):1252-6. doi: 10.1128/AAC.02399-13. Epub 2013 Dec 9.

25.

In vitro activity of ceftaroline-avibactam against gram-negative and gram-positive pathogens isolated from patients in Canadian hospitals from 2010 to 2012: results from the CANWARD surveillance study.

Karlowsky JA, Adam HJ, Baxter MR, Lagacé-Wiens PR, Walkty AJ, Hoban DJ, Zhanel GG.

Antimicrob Agents Chemother. 2013 Nov;57(11):5600-11. doi: 10.1128/AAC.01485-13. Epub 2013 Aug 26.

26.

Evolution and molecular characterization of macrolide-resistant Streptococcus pneumoniae in Canada between 1998 and 2008.

Wierzbowski AK, Karlowsky JA, Adam HJ, Nichol KA, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance.

J Antimicrob Chemother. 2014 Jan;69(1):59-66. doi: 10.1093/jac/dkt332. Epub 2013 Aug 22.

PMID:
23970485
27.

Antimicrobial susceptibility of 22746 pathogens from Canadian hospitals: results of the CANWARD 2007-11 study.

Zhanel GG, Adam HJ, Baxter MR, Fuller J, Nichol KA, Denisuik AJ, Lagacé-Wiens PR, Walkty A, Karlowsky JA, Schweizer F, Hoban DJ; Canadian Antimicrobial Resistance Alliance.

J Antimicrob Chemother. 2013 May;68 Suppl 1:i7-22. doi: 10.1093/jac/dkt022.

PMID:
23587781
28.

Molecular epidemiology of extended-spectrum β-lactamase-, AmpC β-lactamase- and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11.

Denisuik AJ, Lagacé-Wiens PR, Pitout JD, Mulvey MR, Simner PJ, Tailor F, Karlowsky JA, Hoban DJ, Adam HJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance.

J Antimicrob Chemother. 2013 May;68 Suppl 1:i57-65. doi: 10.1093/jac/dkt027.

PMID:
23587779
29.

Changing epidemiology of methicillin-resistant Staphylococcus aureus in Canada.

Nichol KA, Adam HJ, Roscoe DL, Golding GR, Lagacé-Wiens PR, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance.

J Antimicrob Chemother. 2013 May;68 Suppl 1:i47-55. doi: 10.1093/jac/dkt026.

PMID:
23587778
30.

Changes in fluoroquinolone resistance over 5 years (CANWARD 2007-11) in bacterial pathogens isolated in Canadian hospitals.

Karlowsky JA, Adam HJ, Desjardins M, Lagacé-Wiens PR, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance.

J Antimicrob Chemother. 2013 May;68 Suppl 1:i39-46. doi: 10.1093/jac/dkt025.

PMID:
23587777
31.

Comparison of pathogens and their antimicrobial resistance patterns in paediatric, adult and elderly patients in Canadian hospitals.

Adam HJ, Baxter MR, Davidson RJ, Rubinstein E, Fanella S, Karlowsky JA, Lagacé-Wiens PR, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA).

J Antimicrob Chemother. 2013 May;68 Suppl 1:i31-7. doi: 10.1093/jac/dkt024.

PMID:
23587776
32.

Trends in antibiotic resistance over time among pathogens from Canadian hospitals: results of the CANWARD study 2007-11.

Lagacé-Wiens PR, Adam HJ, Low DE, Blondeau JM, Baxter MR, Denisuik AJ, Nichol KA, Walkty A, Karlowsky JA, Mulvey MR, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance.

J Antimicrob Chemother. 2013 May;68 Suppl 1:i23-9. doi: 10.1093/jac/dkt023.

PMID:
23587775
33.

Identification of blood culture isolates directly from positive blood cultures by use of matrix-assisted laser desorption ionization-time of flight mass spectrometry and a commercial extraction system: analysis of performance, cost, and turnaround time.

Lagacé-Wiens PR, Adam HJ, Karlowsky JA, Nichol KA, Pang PF, Guenther J, Webb AA, Miller C, Alfa MJ.

J Clin Microbiol. 2012 Oct;50(10):3324-8. doi: 10.1128/JCM.01479-12. Epub 2012 Aug 8.

34.

Baseline epidemiology of Streptococcus pneumoniae serotypes in Canada prior to the introduction of the 13-valent pneumococcal vaccine.

Adam HJ, Karlowsky JA, Nichol KA, Gilmour MW, Hoban DJ, Embree J, Zhanel GG.

Microb Drug Resist. 2012 Apr;18(2):176-82. doi: 10.1089/mdr.2011.0197. Epub 2011 Dec 28.

PMID:
22204595
35.

Prevalence of antimicrobial resistance among clinical isolates of Bacteroides fragilis group in Canada in 2010-2011: CANWARD surveillance study.

Karlowsky JA, Walkty AJ, Adam HJ, Baxter MR, Hoban DJ, Zhanel GG.

Antimicrob Agents Chemother. 2012 Mar;56(3):1247-52. doi: 10.1128/AAC.05823-11. Epub 2011 Dec 27.

36.

Antimicrobial resistance in urinary tract pathogens in Canada from 2007 to 2009: CANWARD surveillance study.

Karlowsky JA, Lagacé-Wiens PR, Simner PJ, DeCorby MR, Adam HJ, Walkty A, Hoban DJ, Zhanel GG.

Antimicrob Agents Chemother. 2011 Jul;55(7):3169-75. doi: 10.1128/AAC.00066-11. Epub 2011 May 2.

37.

In vitro activity of ceftaroline against gram-positive and gram-negative pathogens isolated from patients in Canadian hospitals in 2009.

Karlowsky JA, Adam HJ, Decorby MR, Lagacé-Wiens PR, Hoban DJ, Zhanel GG.

Antimicrob Agents Chemother. 2011 Jun;55(6):2837-46. doi: 10.1128/AAC.01787-10. Epub 2011 Mar 14.

38.

In vitro activity of ceftobiprole against frequently encountered aerobic and facultative Gram-positive and Gram-negative bacterial pathogens: results of the CANWARD 2007-2009 study.

Walkty A, Adam HJ, Laverdière M, Karlowsky JA, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA).

Diagn Microbiol Infect Dis. 2011 Mar;69(3):348-55. doi: 10.1016/j.diagmicrobio.2010.10.032.

PMID:
21353964
39.

In vitro activity of dalbavancin and telavancin against staphylococci and streptococci isolated from patients in Canadian hospitals: results of the CANWARD 2007-2009 study.

Karlowsky JA, Adam HJ, Poutanen SM, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA).

Diagn Microbiol Infect Dis. 2011 Mar;69(3):342-7. doi: 10.1016/j.diagmicrobio.2010.10.031.

PMID:
21353963
40.

Characterization of Acinetobacter baumannii and meropenem-resistant Pseudomonas aeruginosa in Canada: results of the CANWARD 2007-2009 study.

McCracken M, Mataseje LF, Loo V, Walkty A, Adam HJ, Hoban DJ, Zhanel GG, Mulvey MR; Canadian Antimicrobial Resistance Alliance (CARA).

Diagn Microbiol Infect Dis. 2011 Mar;69(3):335-41. doi: 10.1016/j.diagmicrobio.2010.10.030.

PMID:
21353962
41.

Prevalence and characterization of extended-spectrum β-lactamase- and AmpC β-lactamase-producing Escherichia coli: results of the CANWARD 2007-2009 study.

Simner PJ, Zhanel GG, Pitout J, Tailor F, McCracken M, Mulvey MR, Lagacé-Wiens PR, Adam HJ, Hoban DJ; Canadian Antimicrobial Resistance Alliance (CARA).

Diagn Microbiol Infect Dis. 2011 Mar;69(3):326-34. doi: 10.1016/j.diagmicrobio.2010.10.029.

PMID:
21353961
42.

Comparison of community-associated and health care-associated methicillin-resistant Staphylococcus aureus in Canada: results of the CANWARD 2007-2009 study.

Nichol KA, Adam HJ, Hussain Z, Mulvey MR, McCracken M, Mataseje LF, Thompson K, Kost S, Lagacé-Wiens PR, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA).

Diagn Microbiol Infect Dis. 2011 Mar;69(3):320-5. doi: 10.1016/j.diagmicrobio.2010.10.028.

PMID:
21353960
43.

Analysis of 3789 in- and outpatient Escherichia coli isolates from across Canada--results of the CANWARD 2007-2009 study.

Lagacé-Wiens PR, Simner PJ, Forward KR, Tailor F, Adam HJ, Decorby M, Karlowsky J, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA).

Diagn Microbiol Infect Dis. 2011 Mar;69(3):314-9. doi: 10.1016/j.diagmicrobio.2010.10.027.

PMID:
21353959
44.

Prevalence of antimicrobial resistant pathogens from blood cultures from Canadian hospitals: results of the CANWARD 2007-2009 study.

Adam HJ, DeCorby M, Rennie R, Karlowsky JA, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA).

Diagn Microbiol Infect Dis. 2011 Mar;69(3):307-13. doi: 10.1016/j.diagmicrobio.2010.10.026.

PMID:
21353958
45.

Antimicrobial susceptibility of 15,644 pathogens from Canadian hospitals: results of the CANWARD 2007-2009 study.

Zhanel GG, Adam HJ, Low DE, Blondeau J, Decorby M, Karlowsky JA, Weshnoweski B, Vashisht R, Wierzbowski A, Hoban DJ; Canadian Antimicrobial Resistance Alliance (CARA).

Diagn Microbiol Infect Dis. 2011 Mar;69(3):291-306. doi: 10.1016/j.diagmicrobio.2010.10.025.

PMID:
21353957
46.

Genotypic characterization of tuberculosis transmission within Toronto's under-housed population, 1997-2008.

Adam HJ, Guthrie JL, Bolotin S, Alexander DC, Stuart R, Pyskir D, Brown EM, Rea E, Chedore P, Jamieson FB.

Int J Tuberc Lung Dis. 2010 Oct;14(10):1350-3.

PMID:
20843430
47.

Changing epidemiology of invasive Haemophilus influenzae in Ontario, Canada: evidence for herd effects and strain replacement due to Hib vaccination.

Adam HJ, Richardson SE, Jamieson FB, Rawte P, Low DE, Fisman DN.

Vaccine. 2010 May 28;28(24):4073-8. doi: 10.1016/j.vaccine.2010.03.075. Epub 2010 Apr 14.

PMID:
20398617
48.

Detection and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates in Canada: results from the Canadian Nosocomial Infection Surveillance Program, 1995-2006.

Adam HJ, Louie L, Watt C, Gravel D, Bryce E, Loeb M, Matlow A, McGeer A, Mulvey MR, Simor AE; Canadian Nosocomial Infection Surveillance Program.

Antimicrob Agents Chemother. 2010 Feb;54(2):945-9. doi: 10.1128/AAC.01316-09. Epub 2009 Nov 30.

49.

Community-associated methicillin-resistant Staphylococcus aureus: prevalence in skin and soft tissue infections at emergency departments in the Greater Toronto Area and associated risk factors.

Adam HJ, Allen VG, Currie A, McGeer AJ, Simor AE, Richardson SE, Louie L, Willey B, Rutledge T, Lee J, Goldman RD, Somers A, Ellis P, Sarabia A, Rizos J, Borgundvaag B, Katz KC; EMERGENT Working Group.

CJEM. 2009 Sep;11(5):439-46.

PMID:
19788788
50.

In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.

Adam HJ, Laing NM, King CR, Lulashnyk B, Hoban DJ, Zhanel GG.

Antimicrob Agents Chemother. 2009 Nov;53(11):4915-20. doi: 10.1128/AAC.00078-09. Epub 2009 Sep 8.

Supplemental Content

Support Center